AF/1654

PTO/SB/17 (05-03) Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known TRANSMITTAI Application Number Filing Date for FY 2003 First Named Inventor Effective 01/01/2003. Patent fees are subject to annual revision. **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Art Unit (\$) 160.980 TOTAL AMOUNT OF PAYMENT P05691US Attorney Docket No. FEE CALCULATION (continued) METHOD OF PAYMENT (check all that apply) Money Order 3. ADDITIONAL FEES Credit card **Other** Small Entity arge Entity Deposit Account: ee **Fee Description** Deposit Code (\$) Code 010535 Account 65 Surcharge - late filing fee or oath 1051 130 2051 Number Deposit Surcharge - late provisional filing fee or 1052 50 2052 Account narmaceuticals. Inc cover sheet Name 130 1053 130 Non-English specification 1053 The Director is authorized to: (check all that apply) 1812 2,520 For filing a request for ex parte reexamination 1812 2,520 Credit any overpayments Charge fee(s) indicated below Requesting publication of SIR prior to 920 1804 920* 1804 Charge any additional fee(s) during the bendency of this application Examiner action Charge fee(s) indicated below, except for the filing fee Requesting publication of SIR after 1805 1.840 1805 1.840 Examiner action to the above-identified deposit account 1251 2251 55 Extension for reply within first month 110 **FEE CALCULATION** 205 Extension for reply within second month 1252 410 2252 1. BASIC FILING FEE 930 2253 465 Extension for reply within third month 1253 Large Entity Small Entity Fee Paid Fee Description Fee Fee Code (\$) 1254 1,450 2254 725 Extension for reply within fourth month Extension for reply within fifth month 1255 1,970 2255 1001 750 2001 375 Utility filing fee 60 2401 1401 320 160 Notice of Appeal 2002 165 1002 330 Design filing fee 1402 320 2402 160 Filing a brief in support of an appeal 1003 520 2003 260 Plant filing fee 140 Request for oral hearing 1403 280 2403 2004 375 Reissue filing fee 1004 750 1451 1,510 1451 1,510 Petition to institute a public use proceeding Provisional filing fee 2005 80 55 Petition to revive - unavoidable 1452 110 2452 **SUBTOTAL (1) | (\$)** 1453 1.300 2453 650 Petition to revive - unintentional 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE 1501 1,300 2501 650 Utility issue fee (or reissue) Fee from Fee Paid Extra Claims 1502 470 2502 235 Design issue fee below

Total Claims X 1503 630 2503 315 Plant issue fee Independent 1460 130 1460 130 Petitions to the Commissioner Multiple Dependent 50 Processing fee under 37 CFR 1.17(q) 1807 50 1807 Large Entity Small Entity 180 Submission of Information Disclosure Stmt 1806 1806 180 Fee Description 40 Recording each patent assignment per Fee Code (\$) Code (\$) 40 8021 8021 property (times number of properties) Claims in excess of 20 1202 18 2202 9 375 Filing a submission after final rejection 1809 750 2809 Independent claims in excess of 3 (37 ČFR 1.129(a)) 1201 84 2201 42 375 For each additional invention to be Multiple dependent claim, if not paid 1203 280 2203 140 1810 750 2810 examined (37 CFR 1.129(b)) Reissue independent claims 1204 2204 84 42 375 Request for Continued Examination (RCE) over original patent 1801 750 2801 900 Request for expedited examination 1802 900 1802 ** Reissue claims in excess of 20 1205 18 2205 of a design application and over original patent Other fee (specify) SUBTOTAL (2) (\$)

1005

(Complete (if applicable) SUBMITTED BY Registration No. Telephone Name (Print/Type) Date Signature 44.830

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**or number previously paid, if greater; For Reissues, see above



Patent Atty Docket Ref.: P05691US1 Amylin Docket No.: 0211-UTL-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant: COOLIDGE, et al.

Group. A.U.:

1654

Serial No.:

09/982,978

Examiner:

ACH CHILL SOUS ON THE SOUS OF Meller, Michael

Filed:

October 22, 2001

Conf. No.:

7246

Title: TREATMENT OF HIBERNATING

MYOCARDIUM AND DIABETIC CARDIOMYOPATHY WITH A

GLP-1 PEPTIDE

Docket No.: P05691US1

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

15

Enclosed herewith are the following documents is response to the final office action mailed

March 11, 2003:

- Fee Transmittal for FY 2003
- Notice of Appeal; and
- Return Postcard.

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage in an envelope addressed to the Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

lame of Person Mailing Paper

Signature of Person Mailing Paper

G:\LEGAL\PATENTS\0211\TRANSMITTAL 061103.DOC

Patent

Atty Docket Ref.: P05691US1 Amylin Docket No.: 0211-UTL-9

No further fees are believed due with the filing of this response, however, if any fee should become due or credit become payable during the pendency of these proceedings, the Examiner is authorized to charge or credit the same to deposit account number 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: June 11, 2003

By: 186 44,830

Molly A. Holman. Ph.D., Reg. No.: 40,022

Senior Patent Counsel

AMYLIN PHARMACEUTICALS, INC.

9373 Towne Centre Drive San Diego, CA 92121 Telephone: (858) 552-2200

Facsimile: (858) 552-1936